Novartis' New Oncology CEO Schaffert Has A Potential Blockbuster Launch On Her Hands
In an interview at Novartis' research campus in Cambridge, Mass., Schaffert spoke about the upcoming launch of Piqray for breast cancer, building in radiopharmaceuticals, Kymriah's ongoing manufacturing challenges and more.
You may also be interested in...
Having had a very fruitful year in terms of regulatory approvals, the Swiss major will reveal how successful its new products have been commercially. Of particular interest will be the performance of eye drug Beovu as it takes on Bayer's rival Eylea.
Zolgensma generated $160m in the third quarter, a strong launch for the gene therapy's first full quarter on the market.
Novartis's Hirawat will join the company as chief medical officer, while Celgene's Vessey will head early research. Bristol's current chief scientific officer Lynch will leave the company in October.